Oral News and Research

RSS

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 in New Orleans, Louisiana.

5 May 2010

Families need to achieve optimal oral health: New study

According to a new study surveying U.S. moms, a significant majority (69 percent) feel meeting the specific oral health care needs of each family member is very important, however, nearly half of moms (48 percent) report using a "one size fits all" approach when it comes to oral health care products in their home.

5 May 2010

Children with hearing loss in one ear have poorer oral language scores: Study

By the time they reach school age, one in 20 children have hearing loss in one ear. That can raise significant hurdles for these children, say the results of a new study at Washington University School of Medicine in St. Louis, because loss of hearing in one ear hurts their ability to comprehend and use language.

5 May 2010

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors, today reported financial results for the first quarter ended March 31, 2010.

5 May 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection. The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Digestive Disease Week in New Orleans, indicated that treatment with fidaxomicin significantly improved the recurrence rate and global cure rate in CDI patients requiring concomitant antibiotics, compared to vancomycin.

5 May 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical Companies, Inc. today reported results for the first quarter ended March 31, 2010.

4 May 2010

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

4 May 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx, Inc. today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of our license and collaboration agreement with Merck & Co., Inc in March 2010.

4 May 2010

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Cempra Pharmaceuticals today announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA (CEM-102, sodium fusidate), the company's oral, anti-methicillin-resistant Staphylococcus aureus antibiotic.

4 May 2010

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Sunesis Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

4 May 2010

Pilot pneumonia-prevention program reduces postoperative pneumonia in hospital surgical ward: Research

The results of new research results published in the April issue of the Journal of the American College of Surgeons show that a pilot pneumonia-prevention program significantly reduced postoperative pneumonia in a hospital surgical ward.

4 May 2010

Approval of personalized therapy for lung cancer in Europe will change way of treatment

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

4 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

Study comparing enteroscopy technologies finds SE quicker than DBE for examining small intestine

Spirus Medical, Inc., a leading developer of diagnostic and therapeutic advancement systems for gastroenterology, announced at Digestive Disease Week 2010 that results from the first-ever prospective study comparing enteroscopy technologies show spiral enteroscopy (SE) to be more than three times faster, on average, than double-balloon enteroscopy (DBE) in examining the small intestine.

4 May 2010

Novel biomarker test predicts risk of disease progression in patients with Crohn's disease

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced new findings supporting a novel, algorithm-based biomarker test that helps clinicians effectively predict the risk of developing aggressive disease in patients with Crohn's disease.

4 May 2010

Algal DHA improves memory function in healthy aging adults: MIDAS

The Memory Improvement with Docosahexaenoic acid Study published online this week in Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that algal DHA improved memory function in healthy aging adults, providing a benefit roughly equivalent to having the learning and memory skills of someone three years younger.

4 May 2010

Updated list of emergency medications and equipment for dental providers

Best practices for managing medical emergencies in dental clinics have evolved over the past decade to account for advances in knowledge and the development of new medications and medical equipment. Morton Rosenberg, DMD, of Tufts University School of Dental Medicine and an expert on dental anesthesiology, integrated existing guidelines with new information to create an updated list of emergency medications and equipment for dental providers, including an emergency preparedness checklist.

4 May 2010

Women taking hormonal contraceptives are at highest risk of FSD: Study

Women taking non-oral and oral hormonal contraceptives were at highest risk of Female Sexual Dysfunction, according to a study of female German medical students published today in The Journal of Sexual Medicine. Interestingly, women taking non-hormonal contraceptives were at lowest risk for FSD, more than women not using any contraceptive.

4 May 2010

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat tartrate, an oral therapy in development to treat Gaucher disease.

4 May 2010

Oral News and Research

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Families need to achieve optimal oral health: New study

Children with hearing loss in one ear have poorer oral language scores: Study

Idera Pharmaceuticals reports net loss of $1.9M for first-quarter 2010

Second fidaxomicin Phase 3 clinical study data in patients with CDI to be presented at DDW 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

Positive results from Phase 2 clinical trial of TAKSTA in patients with ABSSSI

Phase 2 clinical trial data of voreloxin to be presented at 2010 ASCO Annual Meeting: MicroStockProfit.com

Pilot pneumonia-prevention program reduces postoperative pneumonia in hospital surgical ward: Research

Approval of personalized therapy for lung cancer in Europe will change way of treatment

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Study comparing enteroscopy technologies finds SE quicker than DBE for examining small intestine

Novel biomarker test predicts risk of disease progression in patients with Crohn's disease

Algal DHA improves memory function in healthy aging adults: MIDAS

Updated list of emergency medications and equipment for dental providers

Women taking hormonal contraceptives are at highest risk of FSD: Study

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News